日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy

骨外髓外疾病对接受标准治疗嵌合抗原受体T细胞疗法的复发难治性多发性骨髓瘤患者预后的影响

Dima, Danai; Abdallah, Al-Ola; Davis, James A; Awada, Hussein; Goel, Utkarsh; Rashid, Aliya; DeJarnette, Shaun; Anwer, Faiz; Shune, Leyla; Raza, Shahzad; Mahmoudjafari, Zahra; Williams, Louis; Faiman, Beth; McGuirk, Joseph P; Sauter, Craig S; Ahmed, Nausheen; Khouri, Jack; Hashmi, Hamza

Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane

一项III期开放标签随机研究,比较甲磺酸艾立布林与卡培他滨治疗既往接受过蒽环类药物和紫杉烷类药物治疗的局部晚期或转移性乳腺癌患者的疗效。

Kaufman, Peter A; Awada, Ahmad; Twelves, Chris; Yelle, Louise; Perez, Edith A; Velikova, Galina; Olivo, Martin S; He, Yi; Dutcus, Corina E; Cortes, Javier

SNPs at miR-155 binding sites of TYRP1 explain discrepancy between mRNA and protein and refine TYRP1 prognostic value in melanoma

TYRP1 的 miR-155 结合位点的 SNP 解释了 mRNA 和蛋白质之间的差异并改善了 TYRP1 在黑色素瘤中的预后价值

P El Hajj, D Gilot, M Migault, A Theunis, L C van Kempen, F Salés, H Fayyad-Kazan, B Badran, D Larsimont, A Awada, L Bachelot, M-D Galibert, G Ghanem, F Journe

Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial

在一项开放标签随机3期试验中,评估了接受甲磺酸艾立布林或卡培他滨治疗的局部晚期或转移性乳腺癌患者的健康相关生活质量。

Cortes, Javier; Hudgens, Stacie; Twelves, Chris; Perez, Edith A; Awada, Ahmad; Yelle, Louise; McCutcheon, Susan; Kaufman, Peter A; Forsythe, Anna; Velikova, Galina

Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies

艾立布林治疗转移性乳腺癌女性患者的疗效:两项3期研究的汇总分析

Twelves, Chris; Cortes, Javier; Vahdat, Linda; Olivo, Martin; He, Yi; Kaufman, Peter A; Awada, Ahmad

Erratum to: Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer

更正:艾立布林甲磺酸盐作为局部复发或转移性人表皮生长因子受体2阴性乳腺癌一线治疗的II期研究

Twelves, Chris; Cortes, Javier; Vahdat, Linda; Olivo, Martin; He, Yi; Kaufman, Peter A; Awada, Ahmad; Filipović, Aleksandra; Lombardo, Ylenia; Faronato, Monica; Abrahams, Joel; Aboagye, Eric; Nguyen, Quang-De; d’Aqua, Barbara Borda; Ridley, Anne; Green, Andrew; Rahka, Emad; Ellis, Ian; Recchi, Chiara; Przulj, Natasa; Sarajlić, Anida; Alattia, Jean-Rene; Fraering, Patrick; Deonarain, Mahendra; Coombes, R Charles; McIntyre, Kristi; O’Shaughnessy, Joyce; Schwartzberg, Lee; Glück, Stefan; Berrak, Erhan; Song, James X; Cox, David; Vahdat, Linda T

Tyrosinase-related protein 1 mRNA expression in lymph node metastases predicts overall survival in high-risk melanoma patients

淋巴结转移中酪氨酸酶相关蛋白 1 mRNA 的表达可预测高危黑色素瘤患者的总体生存率

P El Hajj, F Journe, M Wiedig, I Laios, F Salès, M-D Galibert, L C Van Kempen, A Spatz, B Badran, D Larsimont, A Awada, G Ghanem

TYRP1 mRNA expression in melanoma metastases correlates with clinical outcome

黑色素瘤转移中的 TYRP1 mRNA 表达与临床结果相关

F Journe, H Id Boufker, L Van Kempen, M-D Galibert, M Wiedig, F Salès, A Theunis, D Nonclercq, A Frau, G Laurent, A Awada, G Ghanem